Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical …
…, RW Jang, K Muro, T Satoh, M Machado, W Sun… - JAMA …, 2018 - jamanetwork.com
Importance Therapeutic options are needed for patients with advanced gastric cancer whose
disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety …
disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety …
[HTML][HTML] Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction …
W Sun, M Powell, PJ O'Dwyer, P Catalano… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The combination of sorafenib with chemotherapy is well-tolerated and is associated
with encouraging response rates in several malignances. Both docetaxel and cisplatin are …
with encouraging response rates in several malignances. Both docetaxel and cisplatin are …
The role of angiogenesis in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is
the second leading cause of cancer-related deaths worldwide. The hypervascular nature of …
the second leading cause of cancer-related deaths worldwide. The hypervascular nature of …
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
…, MP Fishman, B Saboury, UR Teitelbaum, W Sun… - Science, 2011 - science.org
Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly
in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune …
in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
…, W Shaib, P Philip, V Sharma, R Siegel, W Sun… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
W Sun, D Sohal, DG Haller, K Mykulowycz, M Rosen… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Anti‐angiogenesis agents have shown effectiveness in treatment of
hepatocellular carcinoma (HCC). It is important to investigate more effective and safe systemic …
hepatocellular carcinoma (HCC). It is important to investigate more effective and safe systemic …
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern …
W Sun, S Lipsitz, P Catalano, JA Mailliard… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of
chemotherapy for symptomatic patients with progressive disease is uncertain. Patients and …
chemotherapy for symptomatic patients with progressive disease is uncertain. Patients and …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
…, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma
(mPDAC) are needed. This study evaluated dual checkpoint combination therapy in …
(mPDAC) are needed. This study evaluated dual checkpoint combination therapy in …
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma
Purpose: This phase I study investigated the maximum-tolerated dose (MTD), safety,
pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an agonist …
pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an agonist …
Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis
…, R Al-Rajabi, A Saeed, J Baranda, W Sun - JAMA network …, 2020 - jamanetwork.com
Importance Standard therapy for locally advanced rectal cancer includes concurrent
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative …
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An alternative …